U.S. Markets closed

Anika Therapeutics, Inc. (ANIK)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
52.82+0.14 (+0.27%)
At close: 4:00PM EDT
People also watch
AMRICBMHSKAALNYARQL

Anika Therapeutics, Inc.

32 Wiggins Avenue
Bedford, MA 01730
United States
781-457-9000
http://www.anikatherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees122

Key Executives

NameTitlePayExercisedAge
Dr. Charles H. Sherwood Ph.D.CEO & Director1.15MN/A70
Ms. Sylvia CheungChief Financial Officer, Treasurer and Sec.537.4kN/A42
Mr. Dana M. AlexanderChief Operations Officer375.14kN/A41
Dr. Edward S. Ahn Ph.D.Chief Technology & Strategy Officer490.65kN/A45
Mr. Richard HagueChief Commercial Officer527.37kN/A57
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company’s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Corporate Governance

Anika Therapeutics, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 10. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.